6 completed, 4 active not recruiting, 3 recruiting, 3 terminated. 19 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 6, Active not recruiting 4, Recruiting 3, Terminated 3, Withdrawn 2, Unknown 1 |
| Phase 1 | 11 | Completed 4, Active not recruiting 2, Recruiting 2, Withdrawn 2, Unknown 1 |
Follow Refractory B-cell Non-Hodgkin Lymphoma: new trials by email Literature Review of Refractory B-cell Non-Hodgkin Lymphoma trials Research Report on Refractory B-cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma ONC-PluReceptor NK cells - Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-02-24 | 2026-11-03 |
| Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Epcoritamab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Recruiting | Reem Karmali | 34 | 2025-07-25 | 2026-07-08 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy - Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Patrick C. Johnson, MD | 28 | 2023-03-01 | 2026-01-29 |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - CD19 Positive, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-10-03 | 2020-01-29 | |
| Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma CAR-CD19 T Cells - Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | CARsgen Therapeutics Co., Ltd. | 20 | 2019-08-14 | 2023-04-14 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Barbara Ann Karmanos Cancer Institute | 43 | 2017-06-20 | 2026-10-23 |
| R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Academic and Community Cancer Research United | 30 | 2016-05-20 | 2024-07-01 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 20 | 2013-10-09 | 2020-08-04 |
| Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin - Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 64 | 2012-10-25 | 2025-02-28 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 20 | 2011-11-16 | 2021-07-20 |
| Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma Cladribine, Laboratory Biomarker Analysis, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | OHSU Knight Cancer Institute | 57 | 2008-08-01 | 2017-12-11 |
Lymphoma, B-Cell (19) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Mantle-Cell (7) · Lymphoma, Follicular (6) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell, Marginal Zone (4) · Burkitt Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, T-Cell (3) · Hodgkin Disease (2) · Lymphoma, Primary Effusion (2) · Waldenstrom Macroglobulinemia (2) · Leukemia, Lymphoid (1) · Lymphoma (1) · Lymphoma, Large-Cell, Anaplastic (1)
Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Lymphoma (18) · Lymphoma, Non-Hodgkin (16) · Hematologic Diseases (5) · Chronic Disease (4) · Disease Attributes (4) · Leukemia (4) · Leukemia, B-Cell (4) · Pathologic Processes (4)
Rituximab (6) · CT-P10 (5) · Cyclophosphamide (3) · Etoposide (3) · fludarabine (3) · fludarabine phosphate (3) · Carmustine (2) · Cytarabine (2) · Lenalidomide (2) · Magnetic Resonance Spectroscopy (2) · Melphalan (2) · Mycophenolic Acid (2) · Peripheral Blood Stem Cell Transplantation (2) · carmustine, poliferprosan 20 drug combination (2) · AFM13 (1)
Fred Hutchinson Cancer Center (4) · M.D. Anderson Cancer Center (4) · Academic and Community Cancer Research United (2) · Barbara Ann Karmanos Cancer Institute (1) · CARsgen Therapeutics Co., Ltd. (1) · Estrella Immunopharma, Inc. (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Patrick C. Johnson, MD (1) · Reem Karmali (1) · University of Washington (1)
United States (18) · China (1)
Ajay Gopal (2) · Catherine S Diefenbach (1) · Connor Johnson, MD (1) · Dipenkumar Modi, M.D. (1) · Grzegorz S Nowakowski (1) · Jie Jin, Dr. (1) · Jordan Gauthier (1) · Katy Rezvani (1) · Mazyar Shadman (1) · Pei Wang, PhD (1) · Reem Karmali, MD (1) · Stephen D. Smith (1) · Stephen M Ansell (1) · Stephen Spurgeon (1) · Wei Ding (1)
PMID 34515338, PMID 28424162, PMID 31177537, PMID 33785483, PMID 40186077
P01CA044991 (2), P30CA015083 (2), P30CA015704 (2), P30CA016672 (1), P30CA022453 (1), P30CA060553 (1), P30CA069533 (1), P50CA097274 (1), UM1CA186686 (1), UM1CA186709 (1)